The urine-based test combines massively parallel sequencing with proprietary error-reducing technology developed at Johns Hopkins.
The positive coverage determination is one of several the company has received in recent months from various insurance companies for the ConfirmMDx test.
The company had previously said it intended to use the proceeds to continue its development of its solid organ transplant diagnostic AlloSure.
The revenue increase was driven by a rise in urologic cancer testing services, which helped offset a decline in solid tumor testing services.
Under the Color Family Testing Program, family members of patients who tested positive for a gene on Color's hereditary cancer test can be tested for $50.
In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.
Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.
Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.
Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.